Navigation Links
Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line
Date:5/3/2010

personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2009 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2010 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About the Quill(TM) Self-Ret
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... . , The researchers ... semiconductor layer. Quantum dots are small structures that spontaneously emit ... laser pulse is fired at the photonic crystal, its refractive ... in the electromagnetic field around it. This change can speed ... dot. As soon as the refractive index recovers its usual ...
(Date:9/30/2014)... 2014 Pacific Northwest Biotechnology, LLC - ... Global Markets Direct,s, ,Pacific Northwest Biotechnology, LLC - ... of the Pacific Northwest Biotechnology, LLC,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 Over the last ... due to rising R&D budgets and increased acceptance of ... growing pharmaceutical and biotechnology industries are also catalyzing the ... filtration market is expected to grow at a strong ... estimated to be worth $2,532.6 million by 2019. The ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... Emphysema and chronic bronchitis patients to benefit from rapid, ... ... formoterol fumarate -, NAPA, Calif., Oct. ... MYL ), today announced the launch of Perforomist(TM),(formoterol fumarate) Inhalation ...
... Stem Cell Treatment Hospital ... Hope Not Found at Home, BEIJING, Oct. ... center for effective treatment of Parkinson,s,disease using adult ... more,international patients returned home from China with a ...
... Debiopharm Group,(Debiopharm), a global independent biopharmaceutical development ... Professors Minoru,Toyota and Keiichi Nakayama with the ... work. The Awards were presented during the,General ... the JCA in Yokohama,Japan, by Professor Setsuo ...
Cached Biology Technology:Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 2American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 3American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 4Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award 2
(Date:9/30/2014)... This news release is available in German . ... differ in their behavioural response to risky situations such ... Institute for Ornithology now found in a long-term study ... correlates with both metabolic rate and ambient temperature. High ... risk-taking behaviour, as in these scenarios birds were more ...
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
(Date:9/29/2014)... DC Monday, September 29: Between 1970 and ... fish around the globe dropped 52 percent, says ... World Wildlife Fund (WWF). This biodiversity loss occurs ... resource use of high-income countries. , In addition ... report,s data point to other warning signs about ...
Breaking Biology News(10 mins):Risky metabolism 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2
... in imaging technology using a combination of light and ... details inside the body. Access to this level of ... but it also has the potential to help health ... symptoms arise. Details describing this advance are published online ...
... Mich. Late-preterm babies those born between 34 and ... and emotional problems, regardless of maternal IQ or demographics, according ... the current edition of the journal Pediatrics . ... have been associated with such problems before, the study represents ...
... more than 60 guides and anglers in the Florida Keys ... assisting in the annual bonefish census. This year,s count, held ... 25-percent from an 8-year mean estimate of 316,805 bonefish to ... Jerry Ault, a fisheries scientist with the University of Miami,s ...
Cached Biology News:Medical imaging breakthrough uses light and sound to see microscopic details inside our bodies 2Late-preterm babies at greater risk for problems later in childhood 2Fall bonefish census sounds warning bell that warrants careful future monitoring 2
Plasmid expressing the LacZ reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... for stabilizing 400g of purified RNA samples., ... the stabilization of aqueous RNA samples that ... as guanidine, phenol/chloroform, silica, oligo dT etc ... contain all the necessary components for the ...
... The FRT-PGK-gb2-neo-FRT-loxP template is designed ... eukaryotic cells, respectively. It combines a ... resistance in E.coli with a ... resistance in mammalian cells. The prokaryotic ...
Biology Products: